CLASS II Drug recall · Reported 22 Mar 2023 · FDA Enforcement Report
Clobazam Tablets, 10 mg, CIV recalled by Breckenridge Pharmaceutical
Breckenridge Pharmaceutical is recalling Clobazam Tablets, 10 mg, CIV, distributed nationwide in the US. The recall was initiated on 2 Mar 2023 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0462-2023
- FDA event ID
- 91786
- Recalling firm
- Breckenridge Pharmaceutical, Berlin, CT
- Classification
- Class II
- Status
- Terminated
- Recall initiated
- 2 Mar 2023
- FDA classified
- 10 Mar 2023
- Reported
- 22 Mar 2023
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Manufacturing (CGMP) Deviations
- Drug class
- Seizure Medication
Timeline
| 2 Mar 2023 | Recall initiated by company | |
| 10 Mar 2023 | Classified by FDA | +8 days |
| 22 Mar 2023 | Published in enforcement report | +12 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
CGMP Deviations: Potential risk of Cross Contamination
Product as listed by the FDA
Clobazam Tablets, 10 mg, CIV, 100-count bottle, Rx only, Manufactured by Centaur Pharmaceuticals Pvt. Ltd., Pune, INDIA, Distributed by: Breckenridge Pharmaceuticals, Inc., Berlin, CT 06037, NDC 51991-900-01
Where it was distributed
USA nationwide.
Questions about this recall
Why was it recalled?
CGMP Deviations: Potential risk of Cross Contamination
Which lots are affected?
Lot # 5210085, Exp 12/2023; 5210248, Exp 01/2024; 5220796, Exp 07/2025
Where was it sold?
USA nationwide.
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
Other products in this recall event
5 other products · FDA event 91786This product is part of a recall event; the main page for the event is Alprazolam Tablets, USP, 1 mg, CIV recalled.
More recalls from Breckenridge Pharmaceutical
All 35| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Duloxetine Delayed-Release Capsules, USP, 30mg recalledDuloxetine | Breckenridge Pharmaceutical | Nitrosamine Impurity | Nationwide |
| Drug | CLASS II | Duloxetine Delayed-Release Capsules, USP, 60mg recalledDuloxetine | Breckenridge Pharmaceutical | Nitrosamine Impurity | Nationwide |
| Drug | CLASS II | Duloxetine Delayed-Release Capsules USP, 60mg recalledDuloxetine | Breckenridge Pharmaceutical | Nitrosamine Impurity | Nationwide |
| Drug | CLASS II | Duloxetine Delayed-Release Capsules, USP, 60 mg recalledDuloxetine | Breckenridge Pharmaceutical | Nitrosamine Impurity | Nationwide |
| Drug | CLASS II | Duloxetine Delayed-Release Capsules, USP, 60 mg recalledDuloxetine | Breckenridge Pharmaceutical | Nitrosamine Impurity | Nationwide |
Other Clobazam recalls
All 7| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Clobazam Tablets, 10 mg recalled by Amerisource Health ServicesClobazam | Amerisource Health Services | Packaging Defects | Nationwide |
| Drug | CLASS II | Clobazam Tablets, 10 mg recalled by Amerisource Health ServicesClobazam | Amerisource Health Services | Packaging Defects | Nationwide |
| Drug | CLASS II | Clobazam Tablets 10mg recalled by Micro LabsClobazam | Micro Labs | Potency & Assay | Nationwide |
| Drug | CLASS II | Clobazam Tablets, 20 mg, CIV recalled by Breckenridge Pharmaceutical | Breckenridge Pharmaceutical | Manufacturing (CGMP) Deviations | Nationwide |
| Drug | CLASS II | Clobazam Oral Suspension 2.5 mg/mL recalled by VistaPharm | VistaPharm | Potency & Assay | Nationwide |